FDA-Approved Prostate Cancer Drug Treatments
| FDA-APPROVED PROSTATE CANCER TREATMENTS | ||||
|---|---|---|---|---|
| Generic & Class | Brand & Company | Strength | Form | Usual Dose* |
| Alkylating agent | ||||
| estramustine | Emcyt
(Pfizer) |
140mg | caps | 14mg/kg in 3 or 4 divided doses |
| Anthracenedione | ||||
| mitoxantrone | Novantrone
(OSI Pharmaceuticals) |
2mg/mL | soln for IV infusion after dilution | 12–14mg/m² every 21 days |
| Antiandrogens | ||||
| abiraterone acetate | Zytiga
(Janssen Biotech) |
250mg | tabs | 1g once daily (in combination with prednisone 5mg twice daily) on an empty stomach |
| bicalutamide | Casodex
(AstraZeneca) |
50mg | tabs | 50mg daily |
| enzalutamide | Xtandi
(Astellas and Medivation) |
40mg | caps | 160mg once daily |
| flutamide | (various) | 125mg | caps | 250mg every 8 hrs |
| nilutamide | Nilandron
(Sanofi Aventis) |
150mg | tabs | 300mg once daily for 30days, then 150mg once daily, starting day of or day after surgical castration |
| Antimicrotubule agents | ||||
| docetaxel | Taxotere
(Sanofi Aventis) |
40mg/mL | soln for IV infusion after dilution | 75mg/m² once every 3 weeks |
| cabazitaxel | Jevtana
(Sanofi Aventis) |
60mg/1.5mL | soln for IV infusion after dilution | 25mg/m² once every 3 weeks with oral prednisone 10mg daily during treatment |
| Autologous cellular immunotherapy | ||||
| sipuleucel-T | Provenge
(Dendreon) |
Minimum 50 million autologous CD54+ cells activated with PAP-GM-CSF/250mL dose | susp for IV infusion | Autologous use only. Obtain product release from manufacturer, match patient identity on product and Cell Product Disposition form, check expiration date and time on product before infusing. Premedicate 30 minutes before infusion with acetaminophen and antihistamine. Give three doses at 2-week intervals. For each dose: give entire contents of bag by IV infusion over 60 minutes; do not use filter; do not use if clumps do not disperse with gentle mixing. Observe patient for at least 30 minutes after infusion. May interrupt or slow infusion if acute transfusion reaction occurs; do not restart if product at room temp for >3 hours. |
| Estrogens | ||||
| conjugated estrogens | Premarin
(Pfizer) |
0.3mg, 0.45mg, 0.625mg, 0.9mg, 1.25mg | tabs | 1.25mg–2.5mg 3 times daily |
| estradiol | Estrace
(Warner Chilcott) |
0.5mg, 1mg, 2mg | scored tabs | 1–2mg 3 times daily |
| estradiol valerate | Delestrogen
(JHP Pharmaceuticals) |
10mg/mL, 20mg/mL, 40mg/mL | soln for IM inj | 30mg or more every 1 or 2 weeks |
| estrogens, esterified | Menest
(King) |
0.3mg, 0.625mg, 1.25mg, 2.5mg | tabs | 1.25–2.5mg 3 times daily |
| GnRH analogues | ||||
| goserelin acetate | Zoladex
(AstraZeneca) |
3.6mg | SC implant | Advanced prostate cancer: one 3.6mg implant every 28 days or one 10.8mg implant every 12 weeks Stage B2-C prostatic carcinoma (in combination with flutamide): Initially one 3.6mg implant, followed in 28 days by one 10.8mg implant; or may use one 3.6mg implant every 28 days. Treat 8 weeks prior to and during radiotherapy. |
| Zoladex 3-Month 10.8mg
(AstraZeneca) |
10.8mg | |||
| histrelin acetate | Vantas
(Endo) |
50mg | SC implant | Insert 1 implant SC in the inner aspect of the upper arm; remove or replace after 12 months |
| leuprolide acetate | Eligard 7.5mg 1-month
(Sanofi Aventis) |
7.5mg | ext-rel susp for SC inj | 7.5mg SC once per month; or 22.5mg SC once every 3 months; or 30mg SC once every 4 months; or 45mg SC once every 6 months |
| Eligard 22.5mg 3-month
(Sanofi Aventis) |
22.5mg | |||
| Eligard 30mg 4-month
(Sanofi Aventis) |
30mg | |||
| Eligard 45mg 6-month
(Sanofi Aventis) |
45mg | |||
| leuprolide acetate | Lupron Depot 7.5mg
(AbbVie) |
7.5mg | depot susp for IM inj | 7.5mg once a month |
| Lupron Depot–3month 22.5mg
(AbbVie) |
22.5mg | 22.5mg every 3 months (84 days). Do not split doses. | ||
| Lupron Depot–4month 30mg
(AbbVie) |
30mg | 30mg as single dose every 4 months (16 weeks). Do not split doses. | ||
| Lupron Depot - 6month 45mg
(AbbVie) |
45mg | 45mg as a single dose every 6 months (24 weeks). Do not split doses. | ||
| leuprolide acetate | (various) | 5mg/mL | soln for SC inj | 1mg SC daily |
| triptorelin pamoate | Trelstar
(Actavis) |
3.75mg, 11.25mg, 22.5mg | pwd for IM inj after reconstitution | 3.75mg every 4 weeks or 11.25mg every 12 weeks or 22.5mg every 24 weeks |
| GnRH antagonist | ||||
| degarelix | Firmagon
(Ferring) |
80mg/vial, 120mg/vial | pwd for SC inj after reconstitution | Give by SC inj in abdomen once every 28 days; avoid waist and rib areas. Two 120mg injections once, then one 80mg inj once every 28 days. |
| NOTES | ||||
|
* For more detailed dosing information, see drug entry. (Rev. 4/2013) |
||||
